| scholarly article | Q13442814 |
| P50 | author | Cosimo Cumbo | Q95642291 |
| Giorgina Specchia | Q38322931 | ||
| Francesco Albano | Q39925203 | ||
| Luisa Anelli | Q42426570 | ||
| P2860 | cites work | Digital PCR | Q24685020 |
| One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment | Q27692583 | ||
| Quantitation of targets for PCR by use of limiting dilution | Q28189275 | ||
| Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients | Q33814851 | ||
| Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. | Q33834587 | ||
| Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study | Q33899734 | ||
| Absolute quantification by droplet digital PCR versus analog real-time PCR. | Q33988019 | ||
| Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely | Q34109784 | ||
| Chromosome studies on normal and leukemic human leukocytes | Q34262444 | ||
| Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs | Q34304788 | ||
| Chronic myeloid leukaemia as a model of disease evolution in human cancer | Q34631354 | ||
| Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia | Q34781322 | ||
| Droplet Digital PCR for BCR/ABL(P210) Detecting of CML: A High Sensitive Method of the Minimal Residual Disease& Disease Progression. | Q54114473 | ||
| [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease]. | Q54191005 | ||
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. | Q54258510 | ||
| Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. | Q54313466 | ||
| Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array. | Q54348031 | ||
| Decreased TET2 gene expression during chronic myeloid leukemia progression. | Q54357058 | ||
| Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. | Q54491280 | ||
| Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. | Q54551498 | ||
| Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. | Q54982432 | ||
| Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML. | Q55004578 | ||
| Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. | Q55177555 | ||
| Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q56959278 | ||
| A multiplex PCR for improved detection of typical and atypical BCR–ABL fusion transcripts | Q56965941 | ||
| Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia | Q57170496 | ||
| A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs | Q57174285 | ||
| Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation | Q58455677 | ||
| Treatment-free remission with first- and second-generation tyrosine kinase inhibitors | Q58609173 | ||
| A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia | Q59236227 | ||
| Is DNA a better assay for residual disease in chronic myeloid leukemia? | Q59797101 | ||
| BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia | Q59797174 | ||
| Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan | Q59810128 | ||
| The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia | Q60046125 | ||
| Concomitant occurrence of BCR-ABL and JAK2V617F mutation | Q61627778 | ||
| Long-template DNA polymerase chain reaction for the detection of the bcr/abl translocation in patients with chronic myelogenous leukemia | Q73347594 | ||
| Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline | Q87946441 | ||
| Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia | Q88293080 | ||
| The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies | Q89251452 | ||
| Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre | Q89427642 | ||
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia | Q90010384 | ||
| Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities | Q90093217 | ||
| Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? | Q90292627 | ||
| Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches | Q90292729 | ||
| A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients | Q90668344 | ||
| Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia | Q90868570 | ||
| Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript | Q90875245 | ||
| Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia | Q91026403 | ||
| Treatment-Free Remission in CML: the US Perspective | Q91055678 | ||
| Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology | Q91288892 | ||
| Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients | Q91774786 | ||
| Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia | Q91963132 | ||
| Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study | Q92252507 | ||
| Leukemia-derived exosomes: Bringing oncogenic signals to blood cells | Q92285488 | ||
| Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia | Q92744905 | ||
| Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation | Q92868956 | ||
| A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD). | Q50634254 | ||
| Attomolar electrochemical detection of the BCR/ABL fusion gene based on an amplifying self-signal metal nanoparticle-conducting polymer hybrid composite. | Q51441625 | ||
| Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia. | Q51555431 | ||
| Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. | Q52355106 | ||
| New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time. | Q52588545 | ||
| Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. | Q52612544 | ||
| The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells. | Q52659598 | ||
| Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. | Q52714899 | ||
| Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. | Q53042357 | ||
| Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. | Q53114641 | ||
| Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia. | Q53483254 | ||
| Proteomic profiling of exosomes: current perspectives | Q34823982 | ||
| Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. | Q34977308 | ||
| A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR | Q35059443 | ||
| Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). | Q35194464 | ||
| Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice | Q35227216 | ||
| A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia | Q35537083 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. | Q35603605 | ||
| Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling | Q35634885 | ||
| The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. | Q35773205 | ||
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results | Q35849776 | ||
| Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation | Q36008206 | ||
| Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. | Q36263943 | ||
| A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. | Q36302377 | ||
| Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia | Q36600934 | ||
| Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors | Q36862301 | ||
| Best Practices in Chronic Myeloid Leukemia Monitoring and Management | Q36884361 | ||
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. | Q37026032 | ||
| TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing | Q37326100 | ||
| Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial | Q37427140 | ||
| An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia | Q37470879 | ||
| Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease | Q37511071 | ||
| Standardisation of molecular monitoring for chronic myeloid leukaemia | Q37644010 | ||
| Standardized definitions of molecular response in chronic myeloid leukemia. | Q38002704 | ||
| How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. | Q38206284 | ||
| Minimal residual disease testing in hematologic malignancies and solid cancer | Q38220970 | ||
| DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia | Q38265115 | ||
| Natural course and biology of CML. | Q38392667 | ||
| A review of the European LeukemiaNet recommendations for the management of CML. | Q38392676 | ||
| BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro | Q38694287 | ||
| Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology. | Q38701790 | ||
| Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression | Q38787818 | ||
| Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. | Q39588677 | ||
| BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells | Q39665460 | ||
| Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. | Q39795335 | ||
| Moving treatment-free remission into mainstream clinical practice in CML. | Q39889947 | ||
| Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. | Q39961918 | ||
| Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis | Q39967880 | ||
| Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay | Q40123623 | ||
| Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. | Q40161701 | ||
| BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. | Q40294208 | ||
| Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study | Q40296906 | ||
| Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients. | Q40351309 | ||
| An improved PCR method for walking in uncloned genomic DNA. | Q40393519 | ||
| Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study | Q40434005 | ||
| Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia. | Q40449249 | ||
| Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib | Q40752763 | ||
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial | Q40807968 | ||
| Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial | Q40864559 | ||
| Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients | Q40996735 | ||
| A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system | Q41312327 | ||
| Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group | Q41661752 | ||
| Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis | Q41768874 | ||
| Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia | Q42048789 | ||
| Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia | Q42217439 | ||
| Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots | Q42743057 | ||
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial | Q42851077 | ||
| Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. | Q42919964 | ||
| Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. | Q43057245 | ||
| Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. | Q43997460 | ||
| Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response | Q44314383 | ||
| Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease | Q44493549 | ||
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia | Q44611047 | ||
| Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response | Q45348850 | ||
| Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants | Q47096076 | ||
| Electrochemical biosensor for detection of BCR/ABL fusion gene using locked nucleic acids on 4-aminobenzenesulfonic acid-modified glassy carbon electrode | Q47328439 | ||
| NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. | Q47594169 | ||
| Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia | Q48144472 | ||
| How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy | Q48162932 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | chronic myeloid leukemia | Q729735 |
| P304 | page(s) | 3175-3189 | |
| P577 | publication date | 2020-05-06 | |
| P1433 | published in | Cancer Management and Research | Q5031417 |
| P1476 | title | Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances | |
| P478 | volume | 12 |
Search more.